← Leaderboards
David Mark Hockenbery
Fred Hutchinson Cancer Research Center
$14,036,112
Attributed
$16,833,793
Total exposure
11
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,833,793 · 11
By mechanism
R01$11,893,202 · 6
U01$1,760,687 · 1
P50$1,744,987 · 1
R21$821,388 · 2
U54$613,529 · 1
Top collaborators
- David Neal Fredricks3 shared
- Silvia Balbo2 shared
Most similar at Fred Hutchinson Cancer Research Center
Same institution · by research overlap
- David Neal Fredricks$32,421,682
- Toshiyasu Taniguchi$2,984,026
- Philip D Greenberg$5,134,650
- Larry Ray Rohrschneider$7,016,877
- Bruce E Clurman$16,275,505
Others in their field
Top investigators on “Metabolic”
- David M Nathan · Massachusetts Institute Of Technology$157,845,616
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$144,157,234
- Judith S. Currier · University Of California Los Angeles$141,260,706
- John M Lachin · George Washington University$139,991,329
- Randall J Bateman · Washington University$124,168,384
- Carol Nesel · Westat$116,355,411
Research focus
MetabolicInsightMetabolismCellsPathway InteractionsMitochondriaCell LineAffectProteinsResponseGenesLinkTissuesIn VivoLipidsInvestigationClassificationIn VitroMalignant NeoplasmsPhysiologyGene ExpressionHigh RiskMetabolic PathwayEnvironment
Grant awards (41)
Fecal Microbiota Transplantation and Fiber for the Treatment of Graft-versus-host Disease After Hematopoietic Cell Transplantation$1,732,424
R01 · FY2025 · HL
Fecal Microbiota Transplantation and Fiber for the Treatment of Graft-versus-host Disease After Hematopoietic Cell Transplantation$1,696,552
R01 · FY2024 · HL
Fecal Microbiota Transplantation and Fiber for the Treatment of Graft-versus-host Disease After Hematopoietic Cell Transplantation$1,699,475
R01 · FY2023 · HL
Delineating the mechanisms and clinical utility of mtDNA mutagenesis in cancer$241,301
R01 · FY2021 · CA · contact PI
Delineating the mechanisms and clinical utility of mtDNA mutagenesis in cancer$161,299
R01 · FY2021 · CA · contact PI
Role of FA-BRCA pathway in stem cell resistance to acetaldehyde$202,502
R21 · FY2018 · AA · contact PI
Role of FA-BRCA pathway in stem cell resistance to acetaldehyde$264,410
R21 · FY2017 · AA · contact PI
Metabolism, protein and miRNA cross-talk in cell cycle and tumor progression$365,200
R01 · FY2016 · CA · contact PI
Biomarker discovery for mitochondrial toxicants using metabolic footprinting$377,291
R01 · FY2015 · ES · contact PI
Metabolism, protein and miRNA cross-talk in cell cycle and tumor progression$365,200
R01 · FY2015 · CA · contact PI
Biomarker discovery for mitochondrial toxicants using metabolic footprinting$373,821
R01 · FY2014 · ES · contact PI
Metabolism, protein and miRNA cross-talk in cell cycle and tumor progression$354,244
R01 · FY2014 · CA · contact PI
Metabolic alterations in advanced Breast Cancer and response to systemic therapy.$340,614
P50 · FY2014 · CA · contact PI
Biomarker discovery for mitochondrial toxicants using metabolic footprinting$370,345
R01 · FY2013 · ES · contact PI
Metabolism, protein and miRNA cross-talk in cell cycle and tumor progression$343,288
R01 · FY2013 · CA · contact PI
Metabolic alterations in advanced Breast Cancer and response to systemic therapy.$342,269
P50 · FY2013 · CA · contact PI
Metabolic alterations in advanced Breast Cancer and response to systemic therapy.$474,987
P50 · FY2012 · CA · contact PI
Biomarker discovery for mitochondrial toxicants using metabolic footprinting$378,224
R01 · FY2012 · ES · contact PI
Metabolism, protein and miRNA cross-talk in cell cycle and tumor progression$365,200
R01 · FY2012 · CA · contact PI
Biomarker discovery for mitochondrial toxicants using metabolic footprinting$395,592
R01 · FY2011 · ES · contact PI
Metabolic alterations in advanced Breast Cancer and response to systemic therapy.$351,137
P50 · FY2011 · CA · contact PI
Metabolic alterations in advanced Breast Cancer and response to systemic therapy.$235,980
P50 · FY2010 · CA · contact PI
Mechanisms linking Nutrient supply & cell cycle/survival$362,299
U54 · FY2009 · CA · contact PI
Cell Metabolism and Myc induced growth, death, and neoplasia$286,122
R01 · FY2009 · CA · contact PI
Cell Metabolism and Myc induced growth, death, and neoplasia$287,237
R01 · FY2008 · CA · contact PI
Mechanisms linking Nutrient supply & cell cycle/survival$251,230
U54 · FY2008 · CA · contact PI
Cell Metabolism and Myc induced growth, death, and neoplasia$288,319
R01 · FY2007 · CA · contact PI
Regulation of substrate-linked mitochondrial ROS generation$149,571
R21 · FY2007 · CA · contact PI
Cell Metabolism & Myc induced growth death, & neoplasia$298,010
R01 · FY2006 · CA · contact PI
Regulation of substrate-linked mitochondrial ROS generation$204,905
R21 · FY2006 · CA · contact PI
Cell Metabolism &Myc induced growth, death, &neoplasia$320,674
R01 · FY2005 · CA
Small Molecule Inhibitors of BcI xL Survival Protein$450,406
U01 · FY2004 · CA
MITOCHONDRIAL CONTROL OF INTESTINAL APOPTOSIS$237,168
R01 · FY2004 · DK
Small Molecule Inhibitors of BcI xL Survival Protein$437,287
U01 · FY2003 · CA
MITOCHONDRIAL CONTROL OF INTESTINAL APOPTOSIS$237,229
R01 · FY2003 · DK
Small Molecule Inhibitors of BcI xL Survival Protein$424,549
U01 · FY2002 · CA
MITOCHONDRIAL CONTROL OF INTESTINAL APOPTOSIS$237,287
R01 · FY2002 · DK
Small Molecule Inhibitors of BcI xL Survival Protein$448,445
U01 · FY2001 · CA
MITOCHONDRIAL CONTROL OF INTESTINAL APOPTOSIS$237,343
R01 · FY2001 · DK
MITOCHONDRIAL CONTROL OF INTESTINAL APOPTOSIS$6,960
R01 · FY2001 · DK
MITOCHONDRIAL CONTROL OF INTESTINAL APOPTOSIS$237,397
R01 · FY2000 · DK